Sofosbuvir is the first drug that can safely and effectively treat some types of hepatitis C without the need to co-administer interferon pegylated. Clinical studies confirm that for types 1 and 4 hepatitis C, the overall sustained virological response (SVR) rate of the drug in combination with pegylated interferon and azithromycin reaches 90%; for type 2 hepatitis C, the SVR rate of the drug in combination with azithromycin is 89%-95%; for type 3 hepatitis C, the SVR rate of the drug in combination with azithromycin is 61%-63%. Let’s take a look at the hepatitis C drugs sofosbuvir and daclatasvir below.

Daklinza daclatasvir is the first drug to show safety and efficacy in the treatment of genotype 3 HCV infection without the need to co-administer interferon pegylated or azithromycin.

Sofosbuvir and daclatasvir: Suitable for all genotypes, with the best treatment effect. Especially for patients with liver cirrhosis, it is the best choice. The 24-week plan can achieve nearly 100% recovery for all patients. The actual effect of sofosbuvir in the treatment of hepatitis C:

(1) Hepatitis C Subtype 1 (1a or 1b) Treatment Plan: Sofosbuvir, Long-acting interferon, Azithromycin Treatment Duration: 12 weeks Treatment Rate: 90% Vaccine

(2) Hepatitis C Subtype 2 (2a or 2b) Treatment Plan: Sofosbuvir, Azithromycin Treatment Duration: 12 weeks Treatment Rate: 93% Vaccine

(3) Hepatitis C Subtype 3 Treatment Plan: Sofosbuvir, Azithromycin Treatment Duration: 24 weeks Treatment Rate: 84% Vaccine

(4) Hepatitis C Subtype 4 Treatment Plan: Sofosbuvir, Long-acting interferon, Azithromycin Treatment Duration: 12 weeks Treatment Rate: 96% Vaccine

With the development of pharmaceutical technology, the treatment of hepatitis C has reached a new level. Currently, the treatment of hepatitis C can basically forget about the inefficient and intolerable interferon treatment plans of the past. The drug sofosbuvir and daclatasvir not only shortens the treatment time for hepatitis C patients but also improves the treatment efficiency, and it is also hoped that hepatitis C can be completely solved in human history.

Hepatitis C is divided into 6 genotypes. Based on different genotypes, the patient’s own condition, and other factors, doctors select the most suitable medication and formulate the best treatment plan for the patient.

The treatment of hepatitis C with sofosbuvir and daclatasvir, organized by EU countries, is strongly recommended by various environmental health organizations. It is particularly safe and reasonable for patients with special conditions, such as renal insufficiency, liver transplantation, and compensated and decompensated liver cirrhosis. This composition is the most widely used and highest treatment rate interferon-free treatment plan scheme certified by clinical medicine in EU countries, the UK, and related to our country.

For patients with type 2 hepatitis C virus (HCV) infection, the application of sofosbuvir and daclatasvir achieves a treatment rate of 98% in just 12 weeks; for type 3, a high treatment rate of 94% can be achieved after 24 weeks.